The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 18, 2008
Filed:
Jun. 22, 2004
Stephen K. Durham, Manlius, NY (US);
Donna Dambach, Wyncote, PA (US);
Stanley Hefta, Pennington, NJ (US);
Frederic Moulin, Newtown, PA (US);
Ji Gao, Cranbury, NJ (US);
Gregory Opiteck, Lawrenceville, NJ (US);
Stephen M. Storm, Richboro, PA (US);
Leah Ann Garulacan, King of Prussia, PA (US);
Jun-hsiang Lin, Newtown, PA (US);
Stephen K. Durham, Manlius, NY (US);
Donna Dambach, Wyncote, PA (US);
Stanley Hefta, Pennington, NJ (US);
Frederic Moulin, Newtown, PA (US);
Ji Gao, Cranbury, NJ (US);
Gregory Opiteck, Lawrenceville, NJ (US);
Stephen M. Storm, Richboro, PA (US);
Leah Ann Garulacan, King of Prussia, PA (US);
Jun-Hsiang Lin, Newtown, PA (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.